NexImmune, Inc. financial data

Symbol
NEXI on OTC
Location
Gaithersburg, MD
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 07 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 120% % -70%
Debt-to-equity 147% % 417%
Return On Equity -542% % -235%
Return On Assets -217% % -72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,394,671 shares -95%
Common Stock, Shares, Outstanding 1,394,671 shares -95%
Common Stock, Value, Issued $139 USD -95%
Weighted Average Number of Shares Outstanding, Basic 1,380,395 shares 32%
Weighted Average Number of Shares Outstanding, Diluted 1,380,395 shares 32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $9,669,244 USD -73%
General and Administrative Expense $10,490,875 USD -24%
Operating Income (Loss) $21,630,326 USD 56%
Nonoperating Income (Expense) $1,013,476 USD 5.6%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $20,616,850 USD 58%
Earnings Per Share, Basic -19 USD/shares 77%
Earnings Per Share, Diluted -19 USD/shares 77%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,424,112 USD -85%
Other Assets, Current $40,640 USD -87%
Assets, Current $3,126,863 USD -83%
Property, Plant and Equipment, Net $1,106,608 USD -72%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $1,627,829 USD 442%
Assets $5,861,300 USD -75%
Accounts Payable, Current $1,281,161 USD 120%
Employee-related Liabilities, Current $351,062 USD -85%
Accrued Liabilities, Current $3,455,430 USD -33%
Liabilities, Current $4,736,591 USD -24%
Liabilities $4,940,761 USD -24%
Retained Earnings (Accumulated Deficit) $227,998,085 USD -9.9%
Stockholders' Equity Attributable to Parent $696,350 USD -96%
Liabilities and Equity $5,861,300 USD -75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,416,058 USD 80%
Net Cash Provided by (Used in) Financing Activities $3,143,949 USD
Net Cash Provided by (Used in) Investing Activities $522,555 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 1,394,671 shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,250,446 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,444,112 USD -85%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Property, Plant and Equipment, Gross $2,669,035 USD -65%
Operating Lease, Liability, Current $0 USD -100%
Preferred Stock, Shares Issued 1 shares
Additional Paid in Capital $228,694,296 USD 1.9%
Preferred Stock, Shares Outstanding 1 shares
Depreciation, Depletion and Amortization $114,912 USD -56%
Share-based Payment Arrangement, Expense $2,348,890 USD -51%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares